Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 7/20 | 0.61 |
| ▸ | KLK1 | P06870 | 2/20 | 0.61 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.61 |
| ▸ | TMPRSS15 | P98073 | 4/20 | 0.52 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | ACR | P10323 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11417275 | 0.94 | PRSS1 (0.67) | PRSS1KLK1TMPRSS2TMPRSS15PRSS2 | |
| SCHEMBL11313907 | 0.91 | PRSS1 (0.49) | PRSS1KLK1TMPRSS2TMPRSS15PRSS2 | |
| SCHEMBL26047455 | 0.88 | KMT2A (0.52) | PRSS1KLK1TMPRSS2TMPRSS15PRSS2 | |
| SCHEMBL10956570 | 0.87 | KMT2A (0.56) | PRSS1PRSS2PRSS3KDM4EKMT2A | |
| SCHEMBL11410222 | 0.87 | SMN1; SMN2 (0.50) | PRSS1KLK1TMPRSS2PRSS2PRSS3 | |
| SCHEMBL11432213 | 0.87 | PRSS1 (0.54) | PRSS1KLK1TMPRSS2TMPRSS15PRSS2 | |
| SCHEMBL11308016 | 0.86 | KMT2A (0.47) | PRSS1KLK1TMPRSS2TMPRSS15PRSS2 | |
| SCHEMBL11309396 | 0.85 | PRSS1 (0.52) | PRSS1KLK1TMPRSS2TMPRSS15PRSS2 | |
| SCHEMBL11569991 | 0.85 | KMT2A (0.54) | PRSS1TMPRSS15PRSS2PRSS3POLB | |
| SCHEMBL15888298 | 0.84 | TMPRSS15 (0.68) | PRSS1TMPRSS15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226005-A1 | Methods of Treating, Ameliorating, Shortening Duration, and/or Reversing Symptoms and/or Complications of a Coronavirus Infection | UNIV YALE (US) | 2023-07-20 | — | — | US | claimed |
| CN-113683537-A | Crystal forms of camostat mesylate and solvates thereof, and preparation methods and applications of crystal forms and solvates thereof | 天津药物研究院有限公司 | 2021-11-23 | — | — | CN | claimed |
| CN-113683534-A | Crystal forms of camostat mesylate and solvates thereof, and preparation methods and applications of crystal forms and solvates thereof | 天津药物研究院有限公司 | 2021-11-23 | — | — | CN | claimed |
| US-20170095440-A1 | METHOD OF TREATING CANINE PANCREATITIS | CK9, LLC | 2017-04-06 | — | — | US | claimed |
| EP-3148524-A1 | METHOD OF TREATING CANINE PANCREATITIS | CK9, LLC (US) | 2017-04-05 | — | — | EP | claimed |
| WO-2015184293-A1 | METHOD OF TREATING CANINE PANCREATITIS | CK9, LLC (US) | 2015-12-03 | — | — | WO | claimed |
| US-6388122-B1 | ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-05-14 | — | — | US | claimed |
| EP-0893437-A1 | TRYPTASE INHIBITOR AND NOVEL GUANIDINO DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-01-27 | — | — | EP | claimed |
| EP-0287036-A2 | New pharmaceutical compositions comprising esters or amides as active ingredients | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-10-19 | — | — | EP | claimed |
| US-4224342-A | ANTI-PLASMIN AND ANTI-TRYPSIN ACTIVITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 1980-09-23 | — | — | US | claimed |
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | OPHIREX, INC (US) | 2026-03-03 | — | — | US | disclosed |
| US-12383531-B2 | PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury | OPHIREX, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250120949-A1 | USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS | OPHIREX, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | OPHIREX, INC (US) | 2025-04-15 | — | — | US | disclosed |
| EP-3448378-B1 | PLA2 AND HMG-COA INHIBITORS FOR TREATMENT OF PATHOLOGICAL CONDITIONS CAUSING HEMOLYSIS, CEREBRAL EDEMA, AND ACUTE KIDNEY INJURY | OPHIREX INC (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-2015184293-A1 | METHOD OF TREATING CANINE PANCREATITIS | CK9, LLC (US) | 2015-12-03 | — | — | WO | disclosed |
| WO-2008142397-A1 | SERINE PROTEASE INHIBITORS FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | SERENTIS LIMITED (GB) | 2008-11-27 | — | — | WO | disclosed |
| US-6388122-B1 | ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-05-14 | — | — | US | disclosed |
| US-4224342-A | ANTI-PLASMIN AND ANTI-TRYPSIN ACTIVITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 1980-09-23 | — | — | US | disclosed |
| JP-S05555154-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | PLA2R1, PLA2G12A, ACHE | PRSS1 70/4885KLK1 379/4885TMPRSS2 63/4885 |
| US-12383531-B2 | PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury | PLA2G4A, PLA2G12A, PLA2G6 | PRSS1 127/4885KLK1 470/4885TMPRSS2 227/4885 |
| US-20230226005-A1 | Methods of Treating, Ameliorating, Shortening Duration, and/or Reversing Symptoms and/or Complications of a Coronavirus Infection | ACE2, ACE, TMPRSS2 | PRSS1 18/4885KLK1 1632/4885TMPRSS2 3/4885 |
| US-20170095440-A1 | METHOD OF TREATING CANINE PANCREATITIS | PNLIP, CEL, PGA5 | PRSS1 92/4885KLK1 2768/4885TMPRSS2 994/4885 |
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | PLA2G12A, PLA2G3, PLA2G1B | PRSS1 36/4885KLK1 982/4885TMPRSS2 10/4885 |
| US-20250120949-A1 | USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS | PLA2G12A, PLA2G2D, PLAAT2 | PRSS1 37/4885KLK1 509/4885TMPRSS2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.